The aging hematopoietic system is characterized by an altered hematopoietic stem cell (HSC) compartment notable for myeloid lineage bias and for an increased incidence of myeloid malignancies([@R1], [@R2]). Previous studies measuring X-inactivation ratios in females identified age-associated skewing (AAS) in blood cells, particularly within the myeloid compartment([@R3], [@R4]). One of several postulated causes of AAS is the acquisition of somatic mutation(s) conferring a growth advantage and resulting in clonal hematopoiesis([@R5]). Recent studies in mice have led investigators to hypothesize that age-related myeloid lineage bias can be explained by clonal expansion of intrinsically myeloid-biased HSCs([@R1], [@R2]). However, a genetic basis for this phenomenon has not been elucidated, nor have recurrent somatic mutations been observed in patients with clonal hematopoiesis without clinically apparent hematopoietic malignancies.

We hypothesized that somatic genetic abnormalities occur in the normal aging population and are a significant cause of AAS in the myeloid compartment. We performed exome sequencing of neutrophils (PMNs) and buccal epithelial cells from three elderly individuals with AAS ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}). In one subject we identified somatic mutations in *TET2, DNMT3A, SLC39A12, ERCC6,* and *KIAA1919* ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We did not identify validated somatic mutations in the other two individuals with median 110x exome sequencing coverage. Importantly, the *TET2* mutation was a nonsense mutation, analogous to the inactivating *TET2* mutations observed in patients with myeloid malignancies ([Figure 1A](#F1){ref-type="fig"} and [Supplementary Figure 1B](#SD1){ref-type="supplementary-material"})([@R6]).

In order to determine if mutations in these genes recur in subjects with AAS, we performed resequencing of all five genes mutated in the index subject in 284 healthy, elderly women aged \>65 years old (179 with X-inactivation skewing, 105 without skewing) and 96 younger women \<60 years-old (all with X-inactivation skewing). We identified missense, nonsense, and frameshift somatic *TET2* mutations, present in granulocyte DNA but not in lymphocyte or buccal DNA, in 10/182 (5.6%) of elderly subjects with AAS, in 0/105 elderly subjects without AAS, and in 0/96 younger subjects with AAS, suggesting that *TET2* mutations are highly enriched in elderly subjects with AAS (p\<0.007; linear logistic) ([Table 1](#T1){ref-type="table"}). Additional somatic mutations in *DNMT3A*, *SLC39A12, ERCC6,* and *KIAA1919* were not observed ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The *TET2* mutation present in each subject was easily detectable as a dominant mutant clone ([Supplementary Figure 1B and 1C](#SD1){ref-type="supplementary-material"}), and in each case X-inactivation patterns at the *HUMARA* locus in PMNs further confirmed that *TET2* mutant individuals had fully skewed X-inactivation consistent with clonally derived hematopoiesis ([Supplementary Methods](#SD1){ref-type="supplementary-material"}). Quantitative Ion Torrent sequencing to measure *TET2* mutant allele burden in patients with *TET2* mutations revealed close concordance with the degree of skewing identified by the HUMARA assay in the majority of subjects studied ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). These data are consistent with recent murine data demonstrating that *Tet2* deletion or haploinsufficiency results in increased HSC self-renewal, competitive growth advantage, and bias towards the myeloid lineage([@R7]--[@R10])

Although *TET2* mutant elderly individuals had X-inactivation ratios compatible with clonal hematopoiesis, hematologic parameters in *TET2* mutant elderly individuals did not differ from age-matched counterparts consistent with the absence of an overt hematological phenotype ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"} and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Notably, we obtained clinical follow-up for 7 of the *TET2* mutant subjects for 5 years or longer after mutational analysis. Although 6 patients remained without clinical evidence of a hematological malignancy, one *TET2* mutant subject subsequently presented with *JAK2V617F*-positive essential thrombocytosis. The increased prevalence of *TET2* mutations in older patients with hematological cancers([@R11]), and the age dependence of *TET2* mutations in our cohort of elderly subjects further support an initiating role for *TET2* mutation in the pathogenesis of age-associated hematological cancers.

TET2 catalyzes the hydroxylation of 5-methylcytosines (5-hmC) throughout the mammalian genome, resulting in loss of DNA methylation (5-mC)([@R12]). Consonant with these functional data we have previously shown *TET2*-mutant acute myeloid leukemia (AML) patients are characterized by a hypermethylation phenotype with site-specific cytosine methylation of target genes. Quantitative mass spectrometric measurement of 5-hydroxymethylcytosine (5-hmC) and 5-mC levels revealed that *TET2* mutant elderly individuals with acquired clonal hematopoiesis (n=6) had reduced 5-hmC compared with younger individuals with skewed X-inactivation ratios (n=10), and increased 5-mC compared with younger clonal individuals or age-matched polyclonal controls (n=15) ([Figure 1B](#F1){ref-type="fig"}). We also observed a decrease in global 5-hmC levels in myeloid cells with age suggesting that decreases in 5-hmC may be an important feature in the aging hematopoietic system, of which acquired *TET2* mutations are one mechanism. In order to determine if the global changes in 5-mC/5-hmC were associated with site-specific changes in promoter methylation, we performed quantitative DNA methylation analysis of loci known to be hypermethylated in AML patients with *TET2* mutations([@R13]). This revealed significant, focal increases in site-specific promoter methylation in elderly subjects with *TET2* mutations (7 individuals with *TET2* mutations and 7 *TET2* wildtype age-matched controls), which were associated with transcriptional silencing of these target genes (n=3 genes) ([Figure 1C](#F1){ref-type="fig"}).

Here we report somatic, recurrent *TET2* mutations in normal elderly individuals with acquired clonal hematopoiesis. These data, in combination with recent studies in murine systems, support a model where *TET2* mutation in a HSC confers enhanced self-renewal and clonal expansion resulting in age-related myeloid lineage bias. More broadly, we report the existence of clonal, somatic mutations in the hematopoietic compartment of normal individuals without overt hematopoietic malignancies. The potential risk of transformation of such mutations must be determined prospectively in larger cohorts of aging individuals, and additional studies will likely identify additional somatic mutations which cause clonal hematopoiesis and which predispose to the development of hematologic malignancies.
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![Somatic *TET2* mutations are present in normal elderly individuals with myeloid skewing and associated with epigenetic alterations\
Exome sequencing identifies somatic *TET2* mutation in myeloid cells of an elderly normal subject with non-random X-inactivation (A). LC/MS analysis reveals a decrease in 5-hmC with age and increased 5-mC in PMNs of elderly individuals with *TET2* mutations (asterisk indicates p\<0.05; arrowheads indicate comparator) (B). This is associated with site-specific hypermethylation and transcriptional silencing (C) in normal individuals with *TET2* mutations as revealed by MassArray Epityper and qRT-PCR analysis in the PMNs of 6 *TET2* wildtype and 6 mutant individuals. Error bars represent standard deviation relative to mean in panels B and C.](nihms403965f1){#F1}
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Details of *TET2* somatic mutations found in normal elderly individuals (n=10)[1](#TFN1){ref-type="table-fn"}.

  Nucleotide substitution     Amino-acid substitution   Chromosome   Position
  --------------------------- ------------------------- ------------ -------------
  c.286_298delCGCACAGTTAGTG   p.Arg96Asnfs\*12          4            106,155,385
  c.1330delA                  p.Thr444Hisfs\*6          4            106,156,429
  c.1348delA                  p.Lys450Lysfs\*2          4            106,156,447
  c.1547delC                  p.Pro516Hisfs\*16         4            106,156,646
  c.1630C\>T                  p.Arg544\*                4            106,156,729
  c.3311_3312insAT            p.Phe1104Leufs\*3         4            106,158,411
  c.3991A\>C                  p.Thr1331Pro              4            106,182,952
  c.5200delA                  p.Met1734Leufs\*11        4            106,196,867
  c.5575insT                  p.Ile1859tyrfs\*16        4            106,197,239
  c.5725G\>T                  p.Glu1909\*               4            106,197,392

Reference sequence used to annotate *TET2* mutations was NM_001127208.

[^1]: These authors contributed equally to this work.
